EyePoint Pharmaceuticals Future Growth

Future criteria checks 2/6

EyePoint Pharmaceuticals's earnings are forecast to decline at 0.01% per annum while its annual revenue is expected to grow at 43.7% per year. EPS is expected to grow by 3.8% per annum. Return on equity is forecast to be -107% in 3 years.

Key information

-0.01%

Earnings growth rate

3.8%

EPS growth rate

Pharmaceuticals earnings growth	17.9%
Revenue growth rate	43.7%
Future return on equity	-107.0%
Analyst coverage	Good
Last updated	01 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:PV3B - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	10	-221	-159	-206	8
12/31/2025	15	-179	-130	-171	11
12/31/2024	42	-118	-121	-131	11
6/30/2024	50	-87	-94	-90	N/A
3/31/2024	50	-79	-17	-12	N/A
12/31/2023	46	-71	-2	2	N/A
9/30/2023	43	-100	9	12	N/A
6/30/2023	37	-106	12	14	N/A
3/31/2023	40	-102	-64	-62	N/A
12/31/2022	41	-102	-67	-65	N/A
9/30/2022	42	-78	-71	-69	N/A
6/30/2022	41	-77	-64	-64	N/A
3/31/2022	39	-67	-55	-55	N/A
12/31/2021	37	-58	-50	-50	N/A
9/30/2021	33	-54	-28	-28	N/A
6/30/2021	39	-42	-19	-19	N/A
3/31/2021	34	-44	-14	-13	N/A
12/31/2020	34	-45	-15	-14	N/A
9/30/2020	36	-40	-32	-32	N/A
6/30/2020	23	-52	-48	-48	N/A
3/31/2020	26	-51	-60	-60	N/A
12/31/2019	20	-57	-57	-57	N/A
9/30/2019	14	-58	-56	-56	N/A
6/30/2019	12	-75	-53	-53	N/A
3/31/2019	6	-98	-42	-42	N/A
12/31/2018	5	-86	-34	-33	N/A
9/30/2018	3	-80	-28	-28	N/A
6/30/2018	3	-53	-22	-22	N/A
3/31/2018	3	-25	N/A	-20	N/A
12/31/2017	3	-23	N/A	-20	N/A
9/30/2017	8	-17	N/A	-20	N/A
6/30/2017	8	-18	N/A	-20	N/A
3/31/2017	7	-19	N/A	-20	N/A
12/31/2016	7	-19	N/A	-20	N/A
9/30/2016	1	-24	N/A	-18	N/A
6/30/2016	2	-22	N/A	-16	N/A
3/31/2016	2	-20	N/A	-15	N/A
12/31/2015	2	-20	N/A	-15	N/A
9/30/2015	2	-19	N/A	10	N/A
6/30/2015	27	6	N/A	10	N/A
3/31/2015	26	8	N/A	11	N/A
12/31/2014	28	10	N/A	13	N/A
9/30/2014	28	11	N/A	-11	N/A
6/30/2014	3	-13	N/A	-11	N/A
3/31/2014	4	-13	N/A	-11	N/A
12/31/2013	2	-14	N/A	-11	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PV3B is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PV3B is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PV3B is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PV3B's revenue (43.7% per year) is forecast to grow faster than the German market (5.5% per year).

High Growth Revenue: PV3B's revenue (43.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PV3B is forecast to be unprofitable in 3 years.

EyePoint Pharmaceuticals Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

EyePoint Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Recent updates

New major risk - Revenue and earnings growth

EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $140.000003 million.

EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $140.000003 million.

EyePoint Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Revenue and earnings growth

EyePoint Pharmaceuticals, Inc. Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema

Eyepoint Pharmaceuticals, Inc. Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of Durasert for the Treatment of Wet Age-Related Macular Degeneration

Now 22% undervalued

EyePoint Pharmaceuticals, Inc. Announces Board Changes

Insider recently bought €90k worth of stock

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

EyePoint Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Second quarter 2024 earnings released: US$0.58 loss per share (vs US$0.61 loss in 2Q 2023)

New major risk - Revenue and earnings growth

New minor risk - Insider selling

EyePoint Pharmaceuticals, Inc. Highlights Duravuyu Clinical and Regulatory Progress and Pipeline Innovation At R&D Day 2024

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.55 loss per share (vs US$0.56 loss in 1Q 2023)

High number of new directors

New major risk - Shareholder dilution

EyePoint Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board

Full year 2023 earnings released: US$1.82 loss per share (vs US$2.74 loss in FY 2022)

EyePoint Pharmaceuticals, Inc. Announces Management Changes

EyePoint Pharmaceuticals, Inc. Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

Executive Vice-Chairman recently sold €802k worth of stock

EyePoint Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Verona Clinical Trial of Eyp-1901 for the Treatment of Diabetic Macular Edema

Executive Vice-Chairman recently sold €384k worth of stock

EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $200.000002 million.

EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $200.000002 million.

EyePoint Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

EyePoint Pharmaceuticals, Inc. Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet Amd Achieving All Primary and Secondary Endpoints

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.33 loss per share (vs US$0.49 loss in 3Q 2022)

EyePoint Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 01, 2023

EyePoint Pharmaceuticals, Inc. Announces Executive Changes

EyePoint Pharmaceuticals, Inc. Reports Positive Masked Safety Update for Lead Product Candidate Eyp-1901 in Ongoing Pavia and Davio 2 Phase 2 Clinical Trials as of September 1, 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.61 loss per share (vs US$0.52 loss in 2Q 2022)

EyePoint Pharmaceuticals, Inc. Announces Interim Masked Safety Data and Patient Baseline Characteristics for EYP-1901

EyePoint Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Eyepoint Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Eyepoint Pharmaceuticals Completes Enrollment in Phase 2 Pavia Clinical Trial of Eyp-1901 in Non-Proliferative Diabetic Retinopathy

Alimera Sciences, Inc. entered into an agreement to acquire YUTIQ® from EyePoint Pharmaceuticals, Inc. for $82.5 million.

Now 20% undervalued

First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.56 loss in 1Q 2022)

Full year 2022 earnings released: US$2.74 loss per share (vs US$2.03 loss in FY 2021)

EyePoint Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Eyepoint Pharmaceuticals Promotes Jay S. Duker, M.D. to President and Chief Operating Officer

High number of new directors

Third quarter 2022 earnings released: US$0.49 loss per share (vs US$0.58 loss in 3Q 2021)

EyePoint Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 02, 2022

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy

Second quarter 2022 earnings released: US$0.52 loss per share (vs US$0.35 loss in 2Q 2021)

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD

EyePoint Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022

EyePoint Pharmaceuticals, Inc. Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

EyePoint Pharmaceuticals, Inc. Appoints Karen Zaderej to Board of Directors

EyePoint Pharmaceuticals Announces Election of Tony Adamis, M.D. to Board of Directors

EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ(R) for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

First quarter 2022 earnings released: US$0.56 loss per share (vs US$0.50 loss in 1Q 2021)

High number of new and inexperienced directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

EyePoint Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Third quarter 2021 earnings released: US$0.58 loss per share (vs US$0.30 loss in 3Q 2020)

EyePoint Pharmaceuticals, Inc. to Present Data At the American Academy of Ophthalmology 2021 Annual Meeting

Second quarter 2021 earnings released: US$0.35 loss per share (vs US$1.04 loss in 2Q 2020)

High number of new directors

Eyepoint Pharmaceuticals, Inc. Announces New Category III CPT Code for DEXYCU® Intraocular Suspension, Approved by the American Medical Association

EyePoint Pharmaceuticals Announces Completion of Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901 for the Potential Treatment of Wet AMD

EyePoint Pharmaceuticals, Inc. announced delayed annual 10-K filing